Home Page

JERSEY CITY, N.J., Nov. 22, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Clinical Trial Planning and Design Services Market By (Trial Phases (Phase I, Phase II, Phase III, and Phase IV), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, And Other Therapeutic Areas), Services (Statistical Analysis Plan, Ecrf, Site Identification And Selection, Medical Writing, And Other Services)) -Trends, Industry Competition Analysis, Revenue, and Forecast To 2030."

According to the latest research by InsightAce Analytic, the global clinical trial planning and design services market size is expected to grow at a CAGR of 8.27% during the forecast period (2022-2030). Clinical trial services are opted for by pharmaceutical companies during the trial of their new drug molecule or molecular analysis of biosimilars before introducing a new drug launch to the market. The rising number of clinical trials, expiry of blockbuster drugs, increasing number of CROs, increasing R&D expenditure in pharmaceutical and biopharmaceutical companies, and rising prevalence of chronic diseases are some of the key factors driving this market. However, the high cost of devices with advanced technologies, stringent government regulations for enrollment of patients, and poor reimbursement policies are expected to downscale the market growth during the forecast period 2022-2030.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1452 

The phase III segment is estimated to dominate the market in 2020 due to the requirement of many participants and high expenses. Advanced planning and designing techniques for clinical trials are increasingly used in various clinical trials. The clinical trial services provide helpful information to the trial conducting pharmaceutical and biotechnology companies. For instance, in July 2021, CD BioSciences, a provider of comprehensive clinical trial services, introduced Randomization Plan Design services for various clinical trials to the scientific and research communities. The newly launched service is expected to help the users to develop a clear and simple randomization plan to ensure its unpredictability and balance and thus reduce or eliminate bias. The oncological disorders segment is estimated to be the fastest-growing therapeutic segment of the clinical trial planning and design services market due to the increasing prevalence of cancer, which leads to growth in novel clinical trial imaging techniques.

Geographically, North America is estimated to dominate the clinical trial planning and design services market in 2021. The segment is expected to have the same growth trend over the forecast period owing to the increasing number of pharmaceutical companies and subsequent increase in their R&D expenditure, increasing prevalence of diseases, and favorable government for clinical trials and research. However, the Asia-Pacific region is expected to be the fastest-growing region due to the rising healthcare expenditure and high demand for clinical trials during the study period.

Some of the key players operating in the clinical trial planning and design services market are Atlantia Clinical Trials, PharmaLex, Emergo UL, Cytel, Health Policy Associate, CD BioSciences, LLX Solutions, SGS, ADM Korea, McDougall Scientific, ClinAsia, BioPoint, IQVIA, PPD, Inc., Veristat, LLC, Clinical Accelerator, Allied Clinical Management GmbH, Parexel International Corporation, Pepgra, WIRB-Copernicus Group, Afortiori Development Ltd, Celerion, CCS (Cardiovascular Clinical Sciences), MCRA, dicentra, DOT WORLD (Japan) and other.

Curious about this latest version of the report?  Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1452 

The market players are focusing on the strategies such as the launch of novel techniques, partnerships, collaborations, and acquisitions to retain their market position. For instance,

• In Sept 2022, Cytel Inc.'s business extended across the Asia-Pacific area (APAC). This enables Cytel's existing biometrics and advanced statistical solutions to be more accessible to APAC biotech and biopharma enterprises. Cytel now has operations in Australia, Shanghai, Beijing, and Singapore, with plans to grow into Seoul and Tokyo in the future. This expansion is the latest move in Cytel's goal to provide advanced analytics capabilities to drug developers worldwide.
• In Sept 2022, Parexel announced the opening of a new clinical trial supplies and logistics facility in Suzhou, China. This strategically positioned facility offers local and international biopharmaceutical companies conducting clinical trials in the region quick access to supplies and investigational therapies to distribute to clinical locations and patients worldwide.
• In March 2022, Emergo by UL created the Optimal Product Usability SuiteTM, a web-based platform (OPUS). This software as a service (SaaS) product provides medical device and technology firms convenient access to human factors engineering (HFE) skills to help with regulatory and commercial initiatives.
• In March 2021, Cytel Inc. launched East® Bayes, an enhanced web-based extension of the East® platform that enables the adoption of the most computationally intensive Bayesian clinical trial designs – without the need for powerful on-site computers. The newly launched web-based extension further expands East's arsenal of Bayesian trial designs by providing a suite of complex phase I dose-escalation and phase II dose-finding designs for greater speed, flexibility, and cost-effectiveness in early clinical development.
• In March 2021, CD BioScences announced that it would offer global early-phase clinical services to researchers. The company claims to advise worldwide scientists through the obstacles of clinical trial development, particularly in reducing time spent in early-phase clinical trials, lowering costs, and lowering potential dangers.
• In Jan 2020, Veristat has expanded its European reach with the acquisition of The Clinical Trial Company (TCTC Group), another CRO. Veristat will obtain ownership of TCTC Group's experience in project management and clinical operations across Europe due to the transaction.

Market Segments

Clinical Trial Planning And Design Services Market Revenue, by Trial Phases, 2019-2030 (Value US$ Mn)

• Phase I
• Phase II
• Phase III
• Phase IV

Clinical Trial Planning And Design Services Market Revenue, by Therapeutic Area, 2019-2030 (Value US$ Mn)

• Oncological Disorders
• Cardiovascular Disorders
• Inflammatory Disorders
• Neurological Disorders
• Other Therapeutic Areas

Clinical Trial Planning And Design Services Market Revenue, by Services, 2019-2030 (Value US$ Mn) 

• Statistical Analysis Plan
• eCRF
• Site Identification and Selection
• Medical Writing
• Other Services

Clinical Trial Planning And Design Services Market Revenue by Region, 2019-2030 (Value US$ Mn) 

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) 

• U.S.
• Canada

Europe Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn)

• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) 

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) 

• Brazil

• Mexico
• Rest of Latin America

Middle East & Africa Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) 

• GCC Countries

• South Africa
• Rest of Middle East & Africa

Why should buy this report:

• To receive a comprehensive analysis of the prospects for the global clinical trial planning and design services market
• To receive industry overview and future trends in clinical trial planning and design services market
• To analyze the global clinical trial planning and design services market drivers and challenges
• To get information on clinical trial planning and design services market size (US$ Mn) and forecast to 2030
• To analyze the significant developments such as investments, mergers & acquisition in clinical trial planning and design services market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1452 

Other Related Reports Published by InsightAce Analytic:

Global Clinical Trials Software Market

Global AI-Based Clinical Trial Solution Providers Market

Global Site Management Organizations (SMO) Market

Global Patient Recruitment and Retention Services Market

Global Clinical Trial Imaging Services Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic Pvt. Ltd.

Tel.: +1 551 226 6109

Email: info@insightaceanalytic.com

Site Visit: www.insightaceanalytic.com

Follow Us on LinkedIn @ bit.ly/2tBXsgS

Follow Us On Facebook @ bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clinical-trial-planning-and-design-services-market-is-projected-to-grow-at-a-cagr-of-8-27-during-the-period-2022-2030--claims-insightace-analytic-301684932.html